The clinical-stage biotechnology company is working on the advancement of a treatment for a blood vessel disorder that it licensed from the other company
This month’s news on technology, partnerships, expansions, and more includes items from IQVIA, Almac Group, Signant Health, Lonza, and other key companies.
The company’s annual survey of pharmaceutical and biotechnology leaders reveals their needs, plans and concerns for the immediate and long-term future.
The CDMO has landed a grant from the Bill and Melinda Gates Foundation’s COVID-19 Therapeutics Accelerator for clinical research in the sub-Saharan region.
Following an inspection at its Ireland site, Almac received compliance certification for its Almac Adapt Just in Time’ clinical packaging and labelling manufacturing services.
Almac joins a working group made up of clinical supply chain industry members, in order to contribute to the use case discussion about blockchain technology.
Almac bolsters its global clinical trial supply management and logistics offering – a market predicted to reach $26bn by 2024, according to a recent report.
In an aim to optimize the performance of changing clinical trials, Almac Clinical Services launched a supply chain solution – Almac Adapt – to provide sponsors with an adaptive supply strategy.
Almac announced it has increased its supply of neo-antigen peptides for individualized cancer treatments with the addition of another stream of GMP manufacturing.
To manage the supply chain challenges faced by natural disasters, experts say to expect the unexpected – ensuring a strong shipping strategy is in place with temperature control and robust management.
Almac Group’s acquisition of BioClin Laboratories expands the company’s analytical services – a growing area of business due to increasing global client requirements, says CDMO.
Almac Clinical Technologies, part of the Almac Group, has announced a collaboration with Exostar to help mitigate risk associated with intellectual property.
More evidence of sponsor demand for direct-to-patient (DTP) services with Marken announcing an expansion of its deal with GlobalCare Clinical Trials just a week after rival Almac launched its to-the-door study drug delivery offering in Europe.
Contract development and manufacturing organisation (CDMO) Almac has invested $7m (€5.5m) in a biocatalysis R&D partnership with Queens University Belfast.
Northern Ireland-based contractor Almac will create 348 jobs over the next five years in its pharma and clinical services business according to UK enterprise, trade and investment Minister, Arlene Foster.
Almac says the completion of a Knowledge Transfer Partnership (KTP) has aided biocatalysis development offering clients an array of streamlined processes.
Genomic analysis seems to be an area of interest for the contract services sector at the moment with Northern Ireland-based Almac and US CRO Quintiles only the latest firms to make investments in the field.
Almac hopes adding high potency API manufacturing capacity at its plant in Craigavon, Northern Ireland will help it retain early phase projects as they move to late-stage development.
Almac Pharma Services has expanded its cold storage capacity for biopharmaceuticals, continuing the contract manufacturing organisation’s (CMO) busy expansion programme.
Contract services firm Almac aims to expand its trial patient management and compliance offering though a new partnership with ePRO specialist Exco InTouch.
Controlled substance supply operations are up and running at Almac’s facility in Souderton, Pennsylvania after the CMO completes the latest stage of relocation to new North American HQ.
In an exclusive Q&A Mark Rohlfing, Almac’s director of Quality, updates Outsourcing-pharma on the firm’s new North American HQ, growth plans and US recruitment drive.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including multiple appointments at Almac and a new chairman at TranScrip Partners.
Almac Diagnostic will use its disease specific assay (DSA) expression profiling technology to help US drug giant Pfizer identify cancer patients who a most responsive to treatment.
Almac claims it can bring drugs to trial faster using an automated approach to compliance that cuts the time taken to validate manufacturing processes by several months.
Almac Sciences, part of global contracting group Almac, chose this year’s Informex in San Francisco, US to showcase its solid state chemistry (SSC) services to drugmakers in North America.
The MHRA has renewed its approval of Almac’s facility in North Carolina, bringing an end to a busy and successful four months of inspections at the clinical services group’s facilities.
